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ABSTRACT: Positron emission tomography (PET) imaging agents that detect amyloid
plaques containing amyloid beta (Aβ) peptide aggregates in the brain of Alzheimer’s
disease (AD) patients have been successfully developed and recently approved by the
FDA for clinical use. However, the short half-lives of the currently used radionuclides 11C
(20.4 min) and 18F (109.8 min) may limit the widespread use of these imaging agents.
Therefore, we have begun to evaluate novel AD diagnostic agents that can be
radiolabeled with 64Cu, a radionuclide with a half-life of 12.7 h, ideal for PET imaging.
Described herein are a series of bifunctional chelators (BFCs), L1−L5, that were designed
to tightly bind 64Cu and shown to interact with Aβ aggregates both in vitro and in transgenic AD mouse brain sections.
Importantly, biodistribution studies show that these compounds exhibit promising brain uptake and rapid clearance in wild-type
mice, and initial microPET imaging studies of transgenic AD mice suggest that these compounds could serve as lead compounds
for the development of improved diagnostic agents for AD.
■ INTRODUCTION
Alzheimer’s disease (AD) is the most common neuro-
degenerative disease and the sixth leading cause of death in
the United States.1,2 Currently, more than 5 million people are
diagnosed with AD in the US, and the number is expected to
reach 15 million by the year 2050. The formation of amyloid
plaques containing the amyloid β (Aβ) peptide is a key
pathological characteristic of the brains of Alzheimer’s
patients.1,3 The main alloforms of the Aβ peptides found in
the amyloid plaques are 40 or 42 amino acids long (Aβ40 and
Aβ42, respectively) with the latter considered to be more
neurotoxic.4,5 According to the amyloid cascade hypothesis, Aβ
aggregation and amyloid plaque formation initiate cellular
events that can lead to neurodegeneration and AD.3,6 However,
recent in vivo studies have shown that the soluble aggregates of
the Aβ peptide, the Aβ oligomers, are possibly most neurotoxic,
their formation being correlated with memory loss and
neurodegeneracy.7,8 Thus, a new dogma in neurobiology has
emerged suggesting that soluble Aβ oligomers,9 rather than
insoluble amyloid ﬁbrils, may be responsible for synaptic
dysfunction and learning deﬁcits in the brains of AD patients
and AD animal models.10,11
Until recently, the unambiguous method to quantify the
extent of amyloid plaque formation involved post-mortem
histopathology techniques. Therefore, development of in vivo
noninvasive positron emission tomography (PET) agents to
identify Aβ plaques in living AD patients was a remarkable
achievement.12−20 However, the only successful radionuclides
to enable this feat exhibit short decay half-lives (11C, t1/2 = 20.4
min and 18F, t1/2= 109.8 min). These radionuclides also require
multiple synthetic steps to be incorporated into the imaging
agent. In this study, a series of bifunctional chelators (BFCs)
were employed to chelate 64Cu and generate PET imaging
agents. 64Cu is a radionuclide with a longer half-life (t1/2 = 12.7
h, β+ = 17%, β− = 39%, EC = 43%, Emax = 0.656 MeV) that can
be considered an ideal PET tracer as long as the proper dose is
administered.21−23 Moreover, the ease of metal chelation
dramatically simpliﬁes the radiosynthesis steps and leads to
PET imaging agents that can be used for longer periods of time
as well as allow their shipment in remote areas. However, the
development of chelators that form Cu complexes stable
enough to face the challenge of transchelation in vivo remains a
diﬃcult task.22 Commonly studied H4DOTA and H4TETA
ligands were shown to form stable complexes of Cu2+ with high
thermodynamic stability, yet they exhibit limited kinetic
inertness.21−23 To obtain more kinetically inert complexes,
cage-like polyazamacrocyclic chelators such as bicyclic hexa-
amines, dicarboxylic acid cross-bridged cyclen, and cyclam have
been subsequently developed, yet these systems require harsher
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radiolabeling conditions.24−29 Most recently, cyclen, 1,4,7-
triazacylononane (TACN), and bispidine ligands were shown
to rapidly form Cu complexes with remarkable inertness.30−32
A great deal of research has been directed to developing
multifunctional radiopharmaceuticals for theranostic applica-
tions.33 These often comprise macrocyclic ligands coupled to
molecular fragments that exhibit aﬃnity for speciﬁc biological
targets.34−43 To that end, we have already shown that BFCs
generated by linking metal-chelating groups to a 2-phenyl-
benzothiazole fragment that resembles the amyloid-binding dye
Thioﬂavin T (ThT) show high aﬃnity for Aβ aggregates and
also bind Cu2+ ions with picomolar aﬃnity.44 Herein, we have
employed the triazacyclononane (TACN) and 2,11-diaza[3.3]-
(2,6)pyridinophane (N4) macrocycles linked to 2-phenyl-
benzothiazole fragments to generate BFCs (Figure 1) that
could be radiolabeled with 64Cu and thus be employed as PET
imaging agents for the detection of Aβ aggregates in vivo. Both
TACN and N4-type compounds have been shown previously
to act as strong metal chelators.33,45,46
■ EXPERIMENTAL SECTION
General Methods. All reagents were purchased from commercial
sources and used as received unless stated otherwise. Solvents were
puriﬁed prior to use by passing through a column of activated alumina
using an MBRAUN SPS. For radiochemistry, ultrapure or trace metal-
grade reagents were obtained from Sigma-Aldrich (St. Louis, MO) and
used as received. All solutions and buﬀers were prepared using water
puriﬁed from a Millipore Integral 5 Milli-Q water system (18 MΩ·cm
resistivity, Billerica, MA). The water was then treated with Chelex
overnight and ﬁltered through a 0.22 μm nylon ﬁlter to remove trace
amounts of metal ions. Whatman 60 Å silica gel thin layer
chromatography (TLC) plates were purchased from Fisher Scientiﬁc
(Pittsburgh, PA) and Radio-TLCs were analyzed using a Bioscan 200
imaging scanner (Bioscan, Inc., Washington, DC). Radioactivity was
counted with a Beckman Gamma 8000 counter containing a NaI
crystal (Beckman Instruments, Inc., Irvine, CA). High-performance
liquid chromatography (HPLC) analysis was performed using Kinetex
(Phenomenex) C-18 column (5 μm, 4.6 × 150 mm I.D.) in Agilent
Technologies 1200 series HPLC equipped with a NaI radiotracer
detector and a photodiode array detector.
Fluorescence Measurements. All ﬂuorescence measurements
were performed using a SpectraMax M2e plate reader (Molecular
Devices). For ThT ﬂuorescence studies, samples were diluted to a ﬁnal
concentration of 2.5 μM Aβ in PBS containing 10 μM ThT, and the
ﬂuorescence measured at 485 nm (λex = 435 nm). For Aβ ﬁbril direct
binding ﬂuorescent studies, a 5 μM Aβ ﬁbril solution was titrated with
various amounts of a compound, and the ﬂuorescence intensity was
measured (λex/λem = 350/450 nm). For ThT competition assays, a 5
μM Aβ ﬁbril solution with 2 μM ThT was titrated with various
amounts of compound, and the ThT ﬂuorescence was measured (λex/
λem = 435/485 nm). For calculating the Ki values, a Kd value of 1.17
μM was used for the binding aﬃnity of ThT to Aβ ﬁbrils.44
Amyloid β Peptide Experiments. Aβ monomeric ﬁlms were
prepared by dissolving commercial Aβ42 or Aβ40 peptide (Keck
Biotechnology Resource Laboratory, Yale University) in 1,1,1,3,3,3-
hexaﬂuoro-2-propanol (HFIP, 1 mM) and incubating for 1 h at room
temperature.47 The solution was then aliquoted out and evaporated
overnight. The aliquots were vacuum centrifuged, and the resulting
monomeric ﬁlms were stored at −80 °C. Aβ ﬁbrils were generated by
dissolving monomeric Aβ ﬁlms in DMSO, diluting into the
appropriate buﬀer, and incubating for 24 h at 37 °C with continuous
agitation (ﬁnal DMSO concentration was <2%).
Fluorescence Imaging of Tg2576 Mice Brain Sections.
Fifteen month old Tg2576 transgenic mice and aged-matched WT
mice brain sections were stained with Congo Red, a known amyloid-
binding dye, and amyloid plaque load was determined according to
previously published protocols.48,49 Stained brain sections were
imaged using a LSM 7010 confocal ﬂuorescent microscope (Zeiss).
The ﬂuorescent images were merged to determine the correlation
between the autoradiography intensity and the ﬂuorescent staining of
the amyloid deposits.
Radiolabeling. 64Cu was produced by a (p,n) reaction on enriched
64Ni on a CS-15 biomedical cyclotron (Cyclotron Corporation,
Berkeley, CA) at Mallinckrodt Institute of Radiology, Washington
University School of Medicine, and puriﬁed with an automated system
using standard procedures.50,51 A stock solution of 64CuCl2 was diluted
with a 10-fold excess of 0.1 M ammonium acetate (NH4OAc), pH 7
for radiolabeling. Labeling of BFCs with 64Cu was achieved by adding
0.01−0.05 μmol of compounds to 37 MBq (1 mCi) of 64CuCl2 in 100
μL of 0.1 M NH4OAc, pH 7. The reactions were incubated on a
thermomixer with 800 rpm agitation at 45 °C for 20 min. Radiolabeled
complexes were analyzed by TLC and high-performance liquid
chromatography (HPLC). Radio-TLCs were developed in acetoni-
trile:water 70:30% v/v mixture and analyzed using a TLC imaging
scanner. Radio-HPLC analysis was performed with a mobile phase of
water (0.1% TFA) and acetonitrile (0.1% TFA), 0−100% acetonitrile
over 20 min, and elution was run for 15 min with a 1 mL/min ﬂow
rate. A radiochemical yield of greater than 95% was achieved for all
labeled compounds, and therefore, they were used without further
puriﬁcation.
Lipophilicity Studies. The 64Cu-labeled complexes (5 μL, 0.37
MBq, 10 μCi) were added to a 1:1 v:v mixture of N-octanol and Milli-
Q water (500 μL/ea). The samples were vortexed at 1,000 rpm for 1 h
and then given 30 min for the layers to separate. Aliquots (100 μL)
from the aqueous and the N-octanol layers were removed and counted
separately in an automated gamma counter. The partition coeﬃcients
were calculated using the ratio of (activity detected in N-octanol)/
(activity detected in aqueous layer) to obtain the logPoct values. The
experiment was conducted in triplicates of triplicates, and the overall
average was recorded as the ﬁnal logPoct value for each compound.
In Vitro Binding Assay with 64Cu-Radiolabeled Complexes.
For blocking studies, the nonradiolabeled compounds 4-hydroxyphe-
nylbenzothiazole (B1) and 4-aminomethyl-phenylbenzothiazole (B2)
were used (Figure S1).52 Aβ40 ﬁbrils (5 μg) were dissolved in 100 μL
of binding buﬀer (10 mM HEPES, 5 mM MgCl2, 1 mM EDTA, 0.1%
BSA, 10 μg/mL of leupeptin, 10 μg/mL of pepstatin, 0.5 μg/mL of
aprotinin, and 200 μg/mL of bacitracin, pH 7.4) and added to 0.1%
polyethylenimine-pretreated wells of a 96-well Multiscreen Durapore
ﬁltration plate (Millipore Corp., Bedford, MA) via vacuum manifold
aspiration. Triplicates were used for each BFC. The wells were washed
three times with wash buﬀer (10 mM HEPES, 1 mM EDTA, 5 mM
MgCl2, 0.1% BSA). After the addition of 5 μg of Aβ40 ﬁbrils to each
well, 0 μg of block, 10 μg of B1, or 10 μg of B2 in a volume of 10 μL of
binding buﬀer was added to triplicate wells. Approximately 500,000
counts per minute (CPM) of 64Cu-labeled BFCs in 100 μL of binding
buﬀer were added to each triplicate well. The plate was incubated at
Figure 1. Structures of the investigated ligands L0 (N4DA) and L1−L5.
The metal-binding and Aβ-interacting fragments are shown in blue
and red, respectively.
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room temperature for 1 h on a shaker, and then the wells were washed
twice with wash buﬀer. The membranes were allowed to dry, removed,
and placed in separate tubes for determination of bound radioactivity.
The radioactivity was counted using an automated gamma counter.
Biodistribution Studies. All animal experiments were performed
in compliance with the Guidelines for Care and Use of Research
Animals established by the Division of Comparative Medicine and the
Animal Studies Committee of Washington University School of
Medicine. Initial biodistribution studies were conducted in wild-type
CD-1 female mice (Charles River Laboratories) of age 5−7 weeks
weighing 25.4 ± 1.4 g. The injection dose was prepared by diluting
into a 90% saline solution. The uptake of 64Cu-labeled compounds was
evaluated in mice (L0, L1, L4, n = 7; L2, L3, L5, n = 3) that were
injected via the tail vein with 0.22−0.37 MBq (6−10 μCi) of each
compound per animal in 100 μL of saline solution. After each time
point (2, 60, and 240 min), mice were anesthetized with 1−2%
isoﬂurane and euthanized by cervical dislocation. The post-PET
biodistribution studies were conducted with 15 month old Tg2576
transgenic mice and aged-matched wild-type (WT) mice, and the
biodistribution counting was performed immediately after the imaging.
Brain, blood, kidney, liver, and other organs of interest were harvested,
and the amount of radioactivity in each organ was counted on a
gamma counter containing a NaI crystal. The data were corrected for
radioactive decay, and the percent injected dose per gram (%ID/g) of
tissue was calculated. All samples were calibrated against a known
standard. Quantitative data were processed by Prism 6 (GraphPad
Software, v 6.03, La Jolla, CA) and expressed as mean ± SEM.
Statistical analysis was performed using one-way analysis of variance
and Student’s t test. Diﬀerences at the 95% conﬁdence level (p < 0.05)
were considered statistically signiﬁcant.
Ex Vivo Autoradiography Studies. Brain sections of 15 month
old Tg2576 transgenic mice and aged-matched WT mice were
obtained as described previously48,49 and immersed into a
cryoprotectant solution. These sections were sorted and carefully
removed using phosphate buﬀer in saline (PBS) with 1% tween-20
solution and mounted onto adhesive glass slides (CFSA 1X, Leica Bio
Systems). Each section was washed with 100% PBS three times, and
∼0.925 MBq (25 μCi) of 64Cu-labeled BFC in 100 μL total volume
was added to completely cover the brain section and incubate for 1 h
at room temperature in a shielded bunker. After the incubation, brain
sections were washed using PBS with ﬁve 1 min cycles and brieﬂy air-
dried. The imaging slides were mounted onto a phosphor imaging
screen plate (GE Healthcare Life Sciences) and exposed for 1−5 min.
The plates were scanned using a phosphor imager plate scanner
(Storm 840), and the resulting images were processed using
ImageQuant 5.2 (Molecular Dynamics) and ImageJ (v1.48, public
domain) software.
PET/CT Imaging Studies. Small animal PET/CT imaging studies
were conducted in Tg2576 transgenic mice weighing 27.3 ± 3.7 g. To
these mice, 2.55−3.70 MBq (69−100 μCi) of 64Cu-labeled BFCs were
administrated via tail vein injection. Mice were anesthetized with 1−
2% isoﬂuorane/oxygen and imaged on an Inveon small animal PET/
CT scanner (Siemens Medical Solutions) for 30 min. Dynamic images
were collected and reconstructed with the maximum aposteriory
probability (MAP) algorithm followed by CT coregistration with the
Inveon Research Workstation image display software (Siemens
Medical Solutions, Knoxville, TN). Regions of interest (ROI) were
selected from PET images with the CT anatomical guidelines, and the
associated radioactivity was measured using Inveon Research Work-
station software. Standard uptake values (SUV) were calculated as
nCi/cc×animal weight/injected dose.
■ RESULTS AND DISCUSSION
Design and Synthesis of BFCs. During the past several
years, we have reported a novel class of bifunctional
compounds (BFCs) that can chelate transition metal ions
and also interact with Aβ aggregates.44,53 For example, the
BFCs L1−L5 were generated using a convergent synthetic route
based on a Mannich reaction between 2-(4-hydroxy-3-
methoxyphenyl-benzothiazole and strong metal chelators such
as 2,4-dimethyl-1,4,7-triazacyclononane (for L2) and 2,11-
diaza[3.3](2,6)-pyridinophane derivatives (for L3−L5) in the
presence of paraformaldehyde (Figure 1).54,55 The 4-hydrox-
yphenyl-benzothiazole molecular structure is derived from
Thioﬂavin T, a well-known amyloid-binding ﬂuorescent dye,
and o-vanilin, a compound shown to have aﬃnity for Aβ
oligomers.56,57 The previously reported metal chelator N,N′-
diacetate-2,11-diaza[3.3](2,6)-pyridinophane (L0 or N4DA)
was employed as a control compound that does not contain
an amyloid-binding fragment.45,46
Interaction of L1−L5 with Aβ Species. First, the in vitro
aﬃnities of BFCs L1−L5 for amyloid ﬁbrils were evaluated. For
this purpose, Aβ40 ﬁbrils were used as they are known to be
fairly homogeneous without any nonﬁbrillar aggregates,58,59
and a ThT ﬂuorescence competition assay was employed to
determine the binding aﬃnity of L1−L5 for Aβ40 ﬁbrils.
44,52,60
Although direct binding ﬂuorescent assays could also be
employed to obtain Kd values for these BFCs (as shown for L1
and L5 in Figures S4 and S5, respectively), the diﬀerent
emission intensities of these compounds hamper a direct
comparison of their aﬃnity for Aβ aggregates. In addition, the
direct binding assays could be complicated due to slightly
diﬀerent binding sites for the various compounds. In the ThT
competition assays, to a solution containing ﬁxed concen-
trations of Aβ40 ﬁbrils and ThT, various amounts of BFC ligand
(0−5 μM) were added, and the decrease in ThT ﬂuorescence
intensity was measured. In our conditions, ThT exhibited an
aﬃnity of Kd = 1.17 ± 0.14 μM for Aβ40 ﬁbrils, similar to
literature values.44 The BFCs L1−L5 exhibit nanomolar aﬃnity
for Aβ40 ﬁbrils with Ki values from 30 to 580 nM (Figure 2 and
Figure 2. ThT ﬂuorescence competition assays for BFCs L1−L5 with
ThT-bound Aβ40 ﬁbrils ([Aβ] = 2 μM, [ThT] = 1 μM). The ﬁts to the
data, along with the corresponding Ki values and goodness of ﬁt, are
given for each plot.
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Table 1). Compounds L2 and L3 show the highest aﬃnity for
Aβ ﬁbrils with Ki values of 30 ± 10 and 40 ± 10 nM,
respectively, whereas L4 and L5 show the lowest aﬃnity with Ki
values of 320 ± 40 and 580 ± 150 nM, respectively. These
results suggest that, for an N4-type BFC containing an amyloid-
binding 2-phenyl-benzothiazole fragment, a small second N-
substituent such as H or CH3 is preferred, because a larger
group such as acetate or even another 2-phenyl-benzothiazole
group may hinder the interaction of the BFC with the β-sheet
structure of the Aβ ﬁbrils. By comparison, the TACN-derived
BFC L1 exhibits a Ki value of 170 ± 50 nM, corresponding to
an aﬃnity for Aβ ﬁbrils that is slightly lower than those of L2
and L3 and that suggests that the N4-type chelator may exhibit
additional interactions with the β-sheet structure of the Aβ
ﬁbrils through pyridine rings of the N4 macrocycle. Although
indeed the Ki values obtained through these ThT ﬂuorescence
competition assays exhibit appreciable error, overall they do
suggest that the investigated BFCs L1−L5 exhibit good aﬃnity
for Aβ40 ﬁbrils in vitro to justify their amyloid-binding
evaluation ex vivo.
Fluorescence Imaging of Amyloid Plaques in Tg2576
AD Mouse Brain Sections. The amyloid-binding properties
of L1−L5 were further probed through ﬂuorescence microscopy
studies by taking advantage of their intrinsic ﬂuorescent
properties.61 For these ex vivo studies, brain sections of 15
month old Tg2576 APP transgenic mice were employed.
Tg2576 mice overexpress a mutant form of amyloid precursor
protein (APP) linked to early onset familial Alzheimer’s disease,
and they develop amyloid plaques and progressive cognitive
impairments.62 Interestingly, an appreciable amount of
ﬂuorescence staining was observed upon incubation of the
brain sections for 30 min with 5 μM solutions of our BFCs
(Figure 3 and Figure S11), especially for L1−L3 (Figure 3, left
panels). The speciﬁc staining of amyloid plaques was conﬁrmed
by staining with Congo Red, another amyloid-binding
ﬂuorescent dye (Figure 3, column 2). Importantly, it seems
that our BFCs might have the ability to stain both dense and
diﬀuse amyloid plaques in vivo, as shown for L1 (white arrows
in the top-right panel of Figure 3), which could be used for the
development of PET imaging agents for early diagnosis of
AD.63 Overall, these ex vivo amyloid binding studies strongly
support the in vitro Aβ ﬁbril binding results and suggest that
these BFCs could be employed in studies in vivo (see below).
Interaction of Cu Complexes of L1−L5 with Aβ
Aggregates. The goal of our studies is to employ 64Cu-
labeled BFCs in PET imaging applications.64−66 In that regard,
we have ﬁrst synthesized and fully characterized the cold Cu
complexes of these BFCs.55 Spectrophotometric titrations
reveal that L1−L5 are extremely strong chelators for Cu2+
with log K stability constants of 27−32 for the corresponding
Cu complexes,55 which are tighter than the common metal
scavengers EDTA and DTPA.67
We have also investigated the Aβ binding aﬃnity of the Cu
complexes of these BFCs. Because Cu2+ ions are well-known to
quench the ﬂuorescence of the Cu-bound ligands, we have
employed ThT competition assays to determine the aﬃnities of
Cu complexes of L1−L5 for Aβ40 ﬁbrils (Table 1). For example,
L1-Cu showed a moderate aﬃnity with a Ki of 765 ± 30 nM
(Figure S6)68 that is only slightly lower than that of free L1 (Ki
= 175 ± 50 nM, Figure 2). Gratifyingly, L2-Cu, L3-Cu, and L5-
Cu complexes all show higher aﬃnities for Aβ40 ﬁbrils with Ki
values of 275 ± 20, 325 ± 25, and 142 ± 55 nM, respectively
(Figures S7, S8, and S10). In contrast, the L4-Cu complex
showed an appreciably lower aﬃnity with Ki of 2.33 ± 0.25 μM
(Figure S9),68 which may due to the change in the charge of
the metal complex upon deprotonation of the carboxylic acid
arm. In contrast, the L5-Cu complex exhibits a higher aﬃnity
for Aβ40 ﬁbrils than the parent L5 compound, likely due to a
rearrangement of the two 2-phenyl-benzothiazole groups upon
Cu binding to allow for a better interaction with the amyloid
ﬁbril structure. Overall, these results conﬁrm that the Cu
complexes of L1−L5 have the ability to interact with Aβ
aggregates with aﬃnities comparable to those of the metal-free
BFCs. Importantly, to the best of our knowledge, this is the ﬁrst
study to report the quantitative determination of Aβ binding
aﬃnities for Cu complexes,64−66 which is an essential in vitro
experiment needed for the development of 64Cu-labeled PET
imaging agents for Aβ aggregates.
Radiolabeling and Log P Value Determination. The
radiolabeling of compounds L0−L5 was performed using
64CuCl2 and employing the conditions described in the
Experimental Section. Quality control assays were conducted
using HPLC and/or TLC, and HPLC retention times were
observed as 5.3, 10.8, 10.9, 10.9, 11.2, and 10.8 min,
respectively, for the 64Cu-radiolabeled L0−L5 complexes
(Figures S12 and S13).68 All radiochemical purities were
>95% within minutes at 45 °C with speciﬁc activities of 100 Ci/
mmol or greater. Therefore, all radiolabeled complexes were
used directly without further puriﬁcation.
Table 1. Properties of Ligands L0−L5, Measured Log Poct
Values for the Corresponding 64Cu-Radiolabeled
Complexes, and Aβ Fibril-Binding Aﬃnity Ki Values for
BFCs and their Cu Complexes (NA = Not Applicable)
ligand MW (g mol−1) log Poct Ki Ln (nM) Ki Cu-Ln (nM)
L0 384.4 −1.09 ± 0.16 NA NA
L1 426.6 0.97 ± 0.12 170 ± 50 765 ± 30
L2 509.6 0.72 ± 0.08 30 ± 10 275 ± 20
L3 523.7 0.64 ± 0.11 40 ± 10 325 ± 25
L4 567.9 0.82 ± 0.05 320 ± 40 2350 ± 250
L5 779.0 0.92 ± 0.07 580 ± 150 142 ± 55
Figure 3. Fluorescence microscopy images of Tg2576 brain sections
incubated with compounds L1, L2, and L3 (left panels), Congo Red
(middle panels), and merged images (right panels). The white arrows
in the top-right panel show the staining by L1 of diﬀuse plaques, which
are not stained signiﬁcantly by Congo Red.
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One important aspect of developing an imaging agent for
Alzheimer’s disease is that it should be able to eﬀectively cross
the blood−brain barrier (BBB).69,70 For the hydrophobicity of
the radiolabeled compounds to be determined, the octanol/
water partition coeﬃcient values log Poct were determined for
the 64Cu complexes of L0−L5 (Table 1). Gratifyingly, the
obtained log Poct values for the
64Cu-radiolabeled complexes
L1−L5 are in the range of 0.64−0.97, which suggests their
potential ability to cross the BBB.71 By comparison, the 64Cu
complex of L0 (N4DA), which does not contain an amyloid-
binding fragment, exhibits a negative log Poct value of −1.09 ±
0.16 and thus is not expected to cross the BBB. We are indeed
aware that compounds with slightly higher log Poct values
(ideally larger than 1) would be desirable, and thus we expect
that simple chemical modiﬁcations of these BFCs should
improve the log Poct values of second-generation compounds by
increasing their hydrophobicity and eventually increasing their
BBB permeability.71
Single Point Binding Assays. The in vitro Aβ binding
aﬃnities of 64Cu-labeled BFCs were determined by incubating
the radiolabeled complexes with a constant amount of Aβ40
ﬁbrils both in the absence and presence of a blocking agent
(Figure 4). The two blocking agents employed, B1 and B2,
contain a 2-phenyl-benzothiazole fragment and exhibit high
aﬃnities for Aβ ﬁbrils (Figures S1−S3).68 Importantly, all BFCs
showed similar uptake values that conﬁrm a tight interaction
with the Aβ ﬁbrils. By contrast, for all compounds except L3,
the signal decreases by at least 60% in the presence of a
blocking agent (especially for B1, which is a more eﬀective
blocking agent than B2) and thus supporting speciﬁc binding to
the Aβ ﬁbrils. Compound L3 shows an appreciable amount of
nonspeciﬁc binding and thus was not employed in subsequent
in vivo imaging studies (see below). Overall, these blocking
studies strongly support the speciﬁc binding of the 64Cu-
radiolabeled BFCs to the Aβ ﬁbrils.
Autoradiography Studies. Ex vivo autoradiography
studies using brain sections of transgenic Tg2576 mice were
also conducted to determine the speciﬁc binding of the 64Cu-
labeled BFCs to the amyloid plaques. The brain sections were
stained, washed, and imaged as described in the Experimental
Section. By comparison to the wild-type brain sections that
show a limited background intensity (Figure 5, second row), an
increased autoradiography intensity was observed upon treat-
ment of the Tg2576 mouse brain sections with the 64Cu-labeled
complexes of L1−L5 (Figure 5, second row). As expected, for
64Cu-L0 that does not bind to amyloid plaques, no marked
diﬀerence was observed between the WT and transgenic mouse
brain sections. The speciﬁc binding to amyloid plaques of the
radiolabeled BFC was further conﬁrmed by blocking with the
nonradioactive blocking agent B1, which led to a markedly
decreased autoradiography intensity (Figure 5, third row).
Finally, the presence of the amyloid plaques toward the edges
of the Tg2576 mouse brain sections was conﬁrmed by
subsequent staining with Congo Red of the brain sections
that were used in the autoradiography studies (Figure 6).
Overall, these autoradiography results strongly suggest that
64Cu-labeled BFCs L1−L5 exhibit the ability to detect Aβ in
vivo.
Biodistribution Studies. Encouraged by the promising in
vitro studies, in vivo biodistribution experiments were
performed to investigate the pharmacokinetics of 64Cu-
radiolabeled L0−L5 complexes using normal CD-1 mice as
described in the Experimental Section. The retention and
accumulation of the 64Cu-radiolabeled complexes in selected
organs were evaluated at 2, 60, and 240 min after tracer
administration (Table 2). Excitingly, appreciable brain uptake
was observed for all BFCs at 2 min post-injection, followed by a
rapid washout from the brains of these wild-type mice (Figure
7). Surprisingly, the brain uptake of 64Cu-L0, albeit low, was
slightly higher than that of 64Cu-L1, likely due to the formation
of a neutral Cu complex for L0 vs a monocationic Cu complex
for L1.
55 Among all BFCs tested, 64Cu-L2 showed the highest
brain uptake of 1.33 ± 0.27% ID/g at 2 min post-injection,
which dropped to 0.27 ± 0.03% ID/g at 60 min. 64Cu-L4 and
64Cu-L5 also showed good brain uptake of 0.61 ± 0.14 and 0.75
Figure 4. Single point in vitro binding studies to evaluate the
speciﬁcity of the 64Cu-radiolabeled ligands for the Aβ ﬁbrils.
Figure 5. Autoradiography images of brain sections of WT and
transgenic mice (Tg2576) in the absence and presence of a known Aβ-
speciﬁc blocking agent (B1).
Figure 6. A representative Tg2576 mouse brain section used for the
autoradiography study with 64Cu-L4 and subsequently stained with
Congo Red to conﬁrm the presence of amyloid plaques close to the
edges of the brain section.
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± 0.16% ID/g at 2 min post-injection, respectively (Figure 7).
Importantly, the brain uptake observed for 64Cu-L2 compares
favorably to those observed recently by Donnelly et al. for 64Cu
complexes of amyloid-binding bis-thiosemicarbazone deriva-
tives.66 It is important to note the appreciable liver uptake of
the 64Cu-labeled L1−L5 compounds (Table 2). Although this
may suggest a somewhat limited stability of the radiolabeled Cu
complexes in vivo, the observed liver uptake also correlates with
the lipophilicity of these 64Cu-labeled BFCs (Table 1). In
addition, the observed liver uptake observed herein is similar to
that observed for 64Cu-labeled DOTA,72 an extensively used Cu
chelator for PET imaging studies.21−23 Overall, these
biodistribution studies strongly suggest that these 64Cu-
radiolabeled compounds can cross the BBB, and thus could
serve as PET imaging agents for detection of Aβ aggregates in
vivo. Importantly, the rapid clearance from the brain of WT
mice suggest that these radiolabeled BFCs do not release 64Cu
ions in the brain to an appreciable extent and thus should not
lead to a signiﬁcant background PET signal in healthy controls.
PET/CT Imaging Studies. In vivo PET imaging studies
were conducted to investigate the brain uptake and activity
distribution of the 64Cu-radiolabeled BFCs L1, L2, L4, and L5 in
Tg2576 transgenic mice (n = 3). Thirty-minute dynamic scans
were conducted following intravenous injection of the radio-
tracers. The PET images are shown in Figure 8, and the PET/
CT-fused maximum intensity projections are shown in Figure
S14. Excitingly, radiotracer accumulation was observed in the
Table 2. Overall Biodistribution Results of 64Cu-Labeled L0−L5 for the Three Time Points Evaluated (2, 60, and 240 min; %
Injected Dose/Gram, Mean ± SEM)
L0 2 min L0 60 min L0 240 min L1 2 min L1 60 min L1 240 min
blood 7.58 ± 0.48 0.96 ± 0.06 0.88 ± 0.01 4.32 ± 0.46 0.98 ± 0.04 1.04 ± 0.19
lung 7.49 ± 0.73 5.14 ± 0.23 5.08 ± 0.55 3.32 ± 0.04 3.67 ± 0.06 4.48 ± 0.31
liver 5.59 ± 0.40 9.87 ± 0.84 7.71 ± 0.37 37.58 ± 3.18 18.03 ± 1.46 10.39 ± 0.75
kidney 33.95 ± 2.09 8.43 ± 0.29 6.98 ± 0.30 73.56 ± 6.98 46.89 ± 2.99 27.92 ± 3.92
muscle 2.55 ± 0.14 0.55 ± 0.03 0.40 ± 0.03 0.74 ± 0.05 0.55 ± 0.18 0.40 ± 0.05
brain 0.37 ± 0.06 0.14 ± 0.01 0.20 ± 0.01 0.17 ± 0.02 0.13 ± 0.01 0.20 ± 0.02
bone 2.66 ± 0.09 1.06 ± 0.09 0.97 ± 0.18 0.69 ± 0.01 0.68 ± 0.02 0.89 ± 0.11
tail 15.51 ± 2.53 3.95 ± 0.38 2.00 ± 0.24 5.32 ± 1.72 2.28 ± 0.69 1.60 ± 0.19
L2 2 min L2 60 min L2 240 min L3 2 min L3 60 min L3 240 min
blood 20.54 ± 1.17 3.66 ± 0.20 2.75 ± 0.20 12.16 ± 1.15 1.26 ± 0.18 1.43 ± 0.26
lung 11.51 ± 0.83 6.93 ± 0.33 8.66 ± 0.92 29.25 ± 1.65 6.85 ± 1.44 7.18 ± 0.31
liver 31.42 ± 5.32 27.13 ± 2.76 24.14 ± 1.55 38.57 ± 1.21 43.36 ± 6.24 35.11 ± 1.07
kidney 31.78 ± 2.26 42.51 ± 1.46 31.10 ± 1.82 35.22 ± 2.13 22.12 ± 3.15 18.56 ± 2.01
muscle 1.25 ± 0.11 0.97 ± 0.08 0.76 ± 0.09 0.77 ± 0.12 0.44 ± 0.04 0.48 ± 0.06
brain 1.33 ± 0.27 0.27 ± 0.03 0.30 ± 0.01 0.49 ± 0.01 0.22 ± 0.04 0.21 ± 0.01
bone 2.09 ± 0.21 1.37 ± 0.04 1.35 ± 0.06 1.30 ± 0.13 1.19 ± 0.33 1.38 ± 0.09
tail 61.81 ± 4.63 15.52 ± 5.02 17.03 ± 6.21 15.00 ± 3.57 14.14 ± 3.58 9.12 ± 1.48
L4 2 min L4 60 min L4 240 min L5 2 min L5 60 min L5 240 min
blood 10.93 ± 0.86 0.99 ± 0.08 0.93 ± 0.07 22.88 ± 2.96 2.53 ± 0.05 2.16 ± 0.03
lung 7.65 ± 0.63 3.92 ± 0.88 4.21 ± 0.30 11.91 ± 1.82 7.20 ± 0.86 10.03 ± 0.34
liver 36.53 ± 2.12 11.60 ± 0.93 9.20 ± 0.53 57.70 ± 4.43 35.83 ± 3.68 26.65 ± 0.17
kidney 17.64 ± 0.52 15.53 ± 1.01 6.23 ± 0.27 79.87 ± 2.80 80.82 ± 12.03 36.69 ± 1.46
muscle 1.67 ± 0.07 0.39 ± 0.03 0.38 ± 0.06 1.38 ± 0.09 0.87 ± 0.05 0.68 ± 0.06
brain 0.61 ± 0.14 0.13 ± 0.01 0.16 ± 0.01 0.75 ± 0.16 0.26 ± 0.01 0.40 ± 0.03
bone 2.47 ± 0.28 0.61 ± 0.12 0.66 ± 0.04 2.31 ± 0.30 1.32 ± 0.05 1.68 ± 0.07
tail 9.20 ± 0.33 5.02 ± 2.02 2.35 ± 0.70 24.57 ± 9.06 24.83 ± 4.68 25.60 ± 8.33
Figure 7. Brain uptake (% ID/g) results from the in vivo
biodistribution study in CD-1 mice at 2 and 60 min post-injection.
Figure 8. Representative coronal, axial, and sagittal PET images of
64Cu-radiolabeled ligands L1, L2, L4, and L5 in Tg2576 transgenic mice
with dynamic scans summed from 1 to 10 min post-injection.
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head and neck area for 64Cu-L2,
64Cu-L4, and
64Cu-L5, whereas
64Cu-L1 showed no appreciable uptake in line with the
biodistribution studies. The maximum brain uptake values
were observed in the 1−8 min window, and then the excess
radioactivity was washed out according to the dynamic scans
(Figures 9). Importantly, the standard uptake value (SUV)
curves clearly indicate that 64Cu-L2 has a signiﬁcantly higher
brain uptake and tracer accumulation compared to those of the
other 64Cu-labeled BFCs. These results correlate well with the
biodistribution studies in wild-type mice and also with the in
vitro amyloid binding experiments that showed L2 has that
highest aﬃnity for Aβ aggregates. This lends promise to the use
of such in vitro assays for rapid screening of the second-
generation BFCs currently being developed in our laboratories
and thus should lead to compounds with improved brain
uptake and Aβ binding properties in vivo. In addition, the use
of transgenic AD mice instead of WT mice in PET imaging
studies seems to be essential for the accurate screening for
imaging agents that show speciﬁcity for amyloid aggregates.66
Post-PET Biodistribution with Tg2576 Transgenic
Mice. After the 30 min PET dynamic scans and 20 min CT
scans, the mice were euthanized and subjected to biodis-
tribution studies. The brain uptake values are shown in Figure
10a, and they correlate well with the end stage (20−30 min
post-injection) standard uptake values from the PET imaging
studies (Figure 10b). Indeed, 64Cu-L2 shows the highest brain
uptake of 0.57 ± 0.05%ID/g in post-PET biodistribution
analysis and an SUV of 1.78 ± 0.09 at 20−30 min from PET in
vivo imaging. These results further conﬁrm the superior ability
of 64Cu-L2 to accumulate in the brain and exhibit a brain uptake
that is signiﬁcantly higher than those of the other radiolabeled
BFCs. Overall, these proof-of-concept PET imaging results
suggest that the 64Cu-radiolabeled BFCs presented here show
an acceptable extent of brain uptake necessary to image Aβ
aggregates in vivo. In addition, we expect that further chemical
modiﬁcations of these ﬁrst-generation BFCs should lead to
compounds with improved physicochemical properties required
for increased brain uptake.
■ CONCLUSIONS
Although a few 11C- and 18F-radiolabeled PET imaging agents
have been recently approved by the FDA as diagnostic agents
for AD, developing novel imaging agents that contain longer-
lived radionuclides for noninvasive PET imaging would be
advantageous for both diagnostic and drug development
purposes. Described here are a series of bifunctional chelators
that were designed to contain a strong chelator for 64Cu and
also contain an amyloid-interacting molecular fragment. The
developed compounds and their Cu complexes were shown to
exhibit low nanomolar aﬃnity for Aβ aggregates in vitro as well
as speciﬁc binding to amyloid plaques in the brain sections of
AD transgenic mice. Moreover, these compounds can be
readily and quantitatively radiolabeled with 64Cu at mild
temperatures, which is an important advantage over other
radiosynthetic approaches. The 64Cu-radiolabeled complexes
also exhibit speciﬁc binding to Aβ aggregates both in vitro and
ex vivo in brain sections of AD transgenic mice, suggesting that
metal complexation does not dramatically aﬀect the amyloid-
binding aﬃnity of these ligands. Most importantly, biodis-
tribution studies have shown that these compounds exhibit
promising brain uptake in wild-type mice followed by rapid
clearance, whereas initial microPET imaging studies of
transgenic AD mice suggest that these compounds could
serve as lead compounds for the development of improved
diagnostic agents for AD. Current eﬀorts focus on the
development of second-generation BFCs with low nanomolar
aﬃnity for various Aβ aggregates and increased brain uptake for
in vivo PET imaging applications.
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Figure 9. Maximum standard uptake value (SUV) time-activity curves
conﬁrming tracer accumulation of 64Cu-radiolabeled L1, L2, L4, and L5
in the brains of Tg2576 transgenic mice (n = 3).
Figure 10. (a) Post-PET biodistribution brain uptakes of 64Cu-L1, -L2,
-L4, and -L5 in Tg2576 transgenic mice (n = 3). (b) Maximum
standard uptake values (t = 20−30 min post-injection) obtained from
dynamic PET imaging. Unpaired t test with Welch’s correction was
used; *p < 0.05, **p < 0.01.
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